Identification

Summary

Sodium phosphate, dibasic is an osmotic laxative used to cleanse the colon before a colonoscopy.

Brand Names
Bss Ophthalmic Solution, Fleet Mineral Oil, Glycerolyte 57, Isolyte S pH 7.4, K-phos Neutral, Osmoprep, Pedia-lax Liquid, Phoxillum, Tis-U-sol
Generic Name
Sodium phosphate, dibasic
DrugBank Accession Number
DB14502
Background

Not Available

Type
Small Molecule
Groups
Approved
Structure
Thumb
Weight
Average: 141.9588
Monoisotopic: 141.940784382
Chemical Formula
HNa2O4P
Synonyms
  • Dibasic sodium phosphate anhydrous
  • Dibasic sodium phosphate, anhydrous
  • Disodium acid phosphate
  • Disodium hydrogen monophosphate
  • Disodium hydrogen phosphate
  • Disodium hydrogen phosphate, anhydrous
  • disodium hydrogenphosphate
  • Disodium phosphate
  • Phosphoric acid, disodium salt, anhydrous
  • Phosphoric acid, sodium salt (1:2)
  • Sodium phosphate dibasic
  • Sodium phosphate, dibasic
  • Sodium phosphate, dibasic (anhydrous)
  • Sodium phosphate, dibasic anhydrous
  • Sodium phosphate, dibasic, anhydrous
  • Sodium phosphate,dibasic,anhydrous
External IDs
  • E-339(II)
  • Fema no. 2398
  • INS NO.339(II)
  • INS-339(II)

Pharmacology

Indication

Used to treat constipation or to clean the bowel before a colonoscopy Label.

Pharmacology
Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Associated Therapies
Contraindications & Blackbox Warnings
Contraindications
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Sodium phosphate inceases fecal water content to increase mobility through the large intestine 1.

Mechanism of action

Sodium phosphate is thought to work by increasing the amount of solute present in the intestinal lumen thereby creating an osmotic gradient which draws water into the lumen 1.

Absorption

Tmax for phosphate absorption with orally administered liquid sodium phosphate is 1-3h 3.

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Adverseeffects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Intamuscular LD50 of 250mg/kg and oral LD50 of 8290 mg/kg reported in rats 7. Phosphate toxicity is likely due to the disturbance of other electrolytes when phosphate levels are high, producing symptoms including tetany, dehydration, hypotension, tachycardia, hyperpyrexia, cardiac arrest and coma 4. Risk of raising phosphate levels through use of sodium phosphate appears to be higher in smaller patients 3.

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AcetazolamideThe risk or severity of adverse effects can be increased when Acetazolamide is combined with Sodium phosphate, dibasic.
AclidiniumThe therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Aclidinium.
AlfentanilThe therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Alfentanil.
AlloinThe risk or severity of adverse effects can be increased when Sodium phosphate, dibasic is combined with Alloin.
AlmasilateThe therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Almasilate.
Aluminium phosphateThe therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Aluminium phosphate.
Aluminum hydroxideThe therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Aluminum hydroxide.
AmantadineThe therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Amantadine.
AmilorideThe risk or severity of adverse effects can be increased when Amiloride is combined with Sodium phosphate, dibasic.
AmiodaroneThe therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Amiodarone.
Interactions
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
  • Take with a full glass of water.
  • Take with food.

Products

Products2
Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Product Ingredients
IngredientUNIICASInChI Key
Sodium phosphate, dibasic dihydrate94255I6E2T10028-24-7KDQPSPMLNJTZAL-UHFFFAOYSA-L
Sodium phosphate, dibasic dodecahydrateE1W4N241FO10039-32-4DGLRDKLJZLEJCY-UHFFFAOYSA-L
Sodium phosphate, dibasic, heptahydrate70WT22SF4B7782-85-6PYLIXCKOHOHGKQ-UHFFFAOYSA-L
Sodium phosphate, dibasic, monohydrateBWZ7K44R51118830-14-1LVXHNCUCBXIIPE-UHFFFAOYSA-L
Active Moieties
NameKindUNIICASInChI Key
Sodium cationionicLYR4M0NH3717341-25-2FKNQFGJONOIPTF-UHFFFAOYSA-N
Phosphate ionionicNK08V8K8HR14265-44-2NBIIXXVUZAFLBC-UHFFFAOYSA-K
Product Images
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
Aminoplasmal B. Braun 10%E Solution for Intravenous InfusionSodium phosphate, dibasic dodecahydrate (3.581 g/1000ml) + Alanine (10.5 g/1000ml) + Arginine (11.5 g/1000ml) + Aspartic acid (5.6 g/1000ml) + Glutamic acid (7.2 g/1000ml) + Glycine (12 g/1000ml) + Histidine (3 g/1000ml) + Isoleucine (5 g/1000ml) + Leucine (8.9 g/1000ml) + Lysine hydrochloride (8.56 g/1000ml) + Magnesium chloride hexahydrate (0.508 g/1000ml) + Methionine (4.4 g/1000ml) + Phenylalanine (4.7 g/1000ml) + Potassium acetate (2.453 g/1000ml) + Proline (5.5 g/1000ml) + Serine (2.3 g/1000ml) + Sodium acetate trihydrate (2.858 g/1000ml) + Sodium hydroxide (0.36 g/1000ml) + Threonine (4.2 g/1000ml) + Tryptophan (1.6 g/1000ml) + Tyrosine (0.4 g/1000ml) + Valine (6.2 g/1000ml)Injection, solutionIntravenousB.BRAUN MEDICAL INDUSTRIES SDN BHD2020-09-08Not applicableMalaysia flag
AMINOPLASMAL B.BRAUN 10% E SOLUTION FOR INFUSIONSodium phosphate, dibasic dodecahydrate (3.581 g/1000ml) + Alanine (10.50 g/1000ml) + Arginine (11.50 g/1000ml) + Aspartic acid (5.60 g/1000ml) + Glutamic acid (7.20 g/1000ml) + Glycine (12.00 g/1000ml) + Histidine (3.00 g/1000ml) + Isoleucine (5.00 g/1000ml) + Leucine (8.90 g/1000ml) + Lysine hydrochloride (8.56 g/1000ml) + Magnesium chloride hexahydrate (0.508 g/1000ml) + Methionine (4.40 g/1000ml) + Phenylalanine (4.70 g/1000ml) + Potassium acetate (2.453 g/1000ml) + Proline (5.50 g/1000ml) + Serine (2.30 g/1000ml) + Sodium acetate trihydrate (2.858 g/1000ml) + Sodium hydroxide (0.360 g/1000ml) + Threonine (4.20 g/1000ml) + Tryptophan (1.60 g/1000ml) + Tyrosine (0.40 g/1000ml) + Valine (6.20 g/1000ml)SolutionIntravenousB. BRAUN SINGAPORE PTE LTD2018-01-23Not applicable
AMINOPLASMAL® 10% ESodium phosphate, dibasic dodecahydrate (3.581 g) + Alanine (10.5 g) + Arginine (11.5 g) + Aspartic acid (5.6 g) + Glutamic acid (7.2 g) + Glycine (12 g) + Histidine (3 g) + Isoleucine (5 g) + Leucine (8.9 g) + Lysine hydrochloride (8.56 g) + Magnesium chloride hexahydrate (0.508 g) + Phenylalanine (4.7 g) + Potassium acetate (2.453 g) + Proline (5.5 g) + Racemethionine (4.4 g) + Serine (2.3 g) + Sodium acetate trihydrate (2.858 g) + Sodium hydroxide (0.36 g) + Threonine (4.2 g) + Tryptophan (1.6 g) + Tyrosine (0.4 g) + Valine (6.2 g)SolutionIntravenousB. BRAUN MEDICAL S.A.2015-07-27Not applicableColombia flag
Aminosyn II 7% M In 10% Dextrose(dual Chamber)Sodium phosphate, dibasic (49 mg / 100 mL) + Alanine (348 mg / 100 mL) + Arginine (356 mg / 100 mL) + Aspartic acid (245 mg / 100 mL) + Dextrose, unspecified form (5 g / 100 mL) + Glutamic acid (258 mg / 100 mL) + Glycine (175 mg / 100 mL) + Histidine (105 mg / 100 mL) + Isoleucine (231 mg / 100 mL) + Leucine (350 mg / 100 mL) + Lysine acetate (368 mg / 100 mL) + Magnesium chloride (30 mg / 100 mL) + Methionine (60 mg / 100 mL) + N-acetyltyrosine (94 mg / 100 mL) + Phenylalanine (104 mg / 100 mL) + Potassium chloride (97 mg / 100 mL) + Proline (252 mg / 100 mL) + Serine (186 mg / 100 mL) + Sodium chloride (120 mg / 100 mL) + Threonine (140 mg / 100 mL) + Tryptophan (70 mg / 100 mL) + Valine (175 mg / 100 mL)SolutionIntravenousHospira Healthcare Ulc1987-12-312012-08-03Canada flag
Aminosyn II 8.5% M In 20% Dextrose (dual Chamber)Sodium phosphate, dibasic (49 mg / 100 mL) + Alanine (422 mg / 100 mL) + Arginine (432 mg / 100 mL) + Aspartic acid (298 mg / 100 mL) + Dextrose, unspecified form (10 g / 100 mL) + Glutamic acid (314 mg / 100 mL) + Glycine (212 mg / 100 mL) + Histidine (128 mg / 100 mL) + Isoleucine (280 mg / 100 mL) + Leucine (425 mg / 100 mL) + Lysine acetate (446 mg / 100 mL) + Magnesium chloride (30 mg / 100 mL) + Methionine (73 mg / 100 mL) + N-acetyltyrosine (115 mg / 100 mL) + Phenylalanine (126 mg / 100 mL) + Potassium chloride (97 mg / 100 mL) + Proline (307 mg / 100 mL) + Serine (225 mg / 100 mL) + Sodium chloride (120 mg / 100 mL) + Threonine (170 mg / 100 mL) + Tryptophan (85 mg / 100 mL) + Valine (212 mg / 100 mL)SolutionIntravenousHospira Healthcare Ulc1987-12-312012-08-03Canada flag
Aminosyn II and DextroseSodium phosphate, dibasic (49.3 mg/100mL) + Alanine (422 mg/100mL) + Arginine (432 mg/100mL) + Aspartic acid (298 mg/100mL) + D-glucose monohydrate (10 g/100mL) + Glutamic acid (314 mg/100mL) + Glycine (212 mg/100mL) + Histidine (128 mg/100mL) + Isoleucine (280 mg/100mL) + Leucine (425 mg/100mL) + Lysine acetate (446 mg/100mL) + Magnesium chloride hexahydrate (30 mg/100mL) + Methionine (73 mg/100mL) + N-acetyltyrosine (115 mg/100mL) + Phenylalanine (126 mg/100mL) + Potassium chloride (97 mg/100mL) + Proline (307 mg/100mL) + Serine (225 mg/100mL) + Sodium chloride (120 mg/100mL) + Threonine (170 mg/100mL) + Tryptophan (85 mg/100mL) + Valine (212 mg/100mL)Injection, solutionIntravenousHospira, Inc.1988-11-012010-01-01US flag
Amo Endosol ExtraSodium phosphate, dibasic (0.42 mg / mL) + Calcium chloride (0.154 mg / mL) + Dextrose, unspecified form (0.92 mg / mL) + Glutathione disulfide (0.184 mg / mL) + Magnesium chloride (0.2 mg / mL) + Potassium chloride (0.38 mg / mL) + Sodium bicarbonate (2.1 mg / mL) + Sodium chloride (7.14 mg / mL)Powder, for solutionIntraocularAmo Canada Company1993-12-312008-07-30Canada flag
BIPHOZYL SOLUTION FOR HAEMODIALYSIS / HAEMOFILTRATIONSodium phosphate, dibasic dihydrate (0.187 g/L) + Magnesium chloride hexahydrate (3.05 g/L) + Potassium chloride (0.314 g/L) + Sodium bicarbonate (2.122 g/L) + Sodium chloride (7.013 g/L)SolutionHemodialysis; IntravenousBAXTER HEALTHCARE (ASIA) PTE LTD2018-07-20Not applicable
Bss PlusSodium phosphate, dibasic (0.042 %) + Calcium chloride (0.0154 %) + Dextrose, unspecified form (0.092 %) + Glutathione disulfide (0.0184 %) + Magnesium chloride (0.02 %) + Potassium chloride (0.038 %) + Sodium bicarbonate (0.21 %) + Sodium chloride (0.714 %)Kit; SolutionIntraocularAlcon, Inc.1982-12-31Not applicableCanada flag
CASEN PHOSPHO-SODA 24.4g/10.8g oral solutionSodium phosphate, dibasic dodecahydrate (24.4 g) + Sodium phosphate, monobasic, dihydrate (10.8 g)SolutionOralPHARMAFORTE (MALAYSIA) SDN. BHD.2020-09-08Not applicableMalaysia flag
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
B.T.ENEMA 210 ML LAVMANSodium phosphate, dibasic (3.5 g/59ml) + Sodium phosphate, monobasic (9.5 g/59ml)EnemaRectalYENİŞEHİR LABORATUARI LTD. ŞTİ.2020-08-14Not applicableTurkey flag
B.T.ENEMA 67,5 ML LAVMANSodium phosphate, dibasic (3.5 g/59ml) + Sodium phosphate, monobasic (9.5 g/59ml)EnemaRectalYENİŞEHİR LABORATUARI LTD. ŞTİ.2020-08-14Not applicableTurkey flag
Dibasic Sodium Phosphate, Monobasic Potassium Phosphate and Monobasic Sodium PhosphateSodium phosphate, dibasic (852 mg/1) + Monopotassium phosphate (155 mg/1) + Sodium phosphate, monobasic, monohydrate (130 mg/1)TabletOralKAISER FOUNDATION HOSPITALS2014-07-072018-01-31US flag
Dibasic Sodium Phosphate, Monobasic Potassium Phosphate and Monobasic Sodium PhosphateSodium phosphate, dibasic (852 mg/1) + Monopotassium phosphate (155 mg/1) + Sodium phosphate, monobasic, monohydrate (130 mg/1)TabletOralCarilion Materials Management2012-06-28Not applicableUS flag64980 0104 01 nlmimage10 cc046643
Dibasic Sodium Phosphate, Monobasic Potassium Phosphate and Monobasic Sodium PhosphateSodium phosphate, dibasic (852 mg/1) + Monopotassium phosphate (155 mg/1) + Sodium phosphate, monobasic, monohydrate (130 mg/1)TabletOralCardinal Health2012-06-282018-03-31US flag55154 767620180907 15195 nnrmgf
Dibasic Sodium Phosphate, Monobasic Potassium Phosphate and Monobasic Sodium PhosphateSodium phosphate, dibasic (852 mg/1) + Monopotassium phosphate (155 mg/1) + Sodium phosphate, monobasic, monohydrate (130 mg/1)TabletOralAmerican Health Packaging2014-05-132020-06-30US flag
Dibasic Sodium Phosphate, Monobasic Potassium Phosphate and Monobasic Sodium PhosphateSodium phosphate, dibasic (852 mg/1) + Monopotassium phosphate (155 mg/1) + Sodium phosphate, monobasic, monohydrate (130 mg/1)TabletOralAvera McKennan Hospital2015-03-112017-05-24US flag69189 010420180907 15195 1028m42
Dibasic Sodium Phosphate, Monobasic Potassium Phosphate and Monobasic Sodium PhosphateSodium phosphate, dibasic (852 mg/1) + Monopotassium phosphate (155 mg/1) + Sodium phosphate, monobasic, monohydrate (130 mg/1)TabletOralRising Pharmaceuticals, Inc.2012-06-28Not applicableUS flag
ISOLYTE SISE 1000 ML(SETLI)Sodium phosphate, dibasic, heptahydrate (0.012 %) + Sodium gluconate (0.5 %) + Magnesium chloride (0.03 %) + Monopotassium phosphate (0.00082 %) + Potassium chloride (0.037 %) + Sodium acetate trihydrate (0.37 %) + Sodium chloride (0.53 %)SolutionIntravenousECZACIBAŞI-BAXTER HASTANE ÜRÜNLERİ SAN.VE TİC. A.Ş.2020-08-14Not applicableTurkey flag
ISOLYTE SISE 1000 ML(SETSIZ)Sodium phosphate, dibasic, heptahydrate (0.012 %) + Sodium gluconate (0.5 %) + Magnesium chloride (0.03 %) + Monopotassium phosphate (0.00082 %) + Potassium chloride (0.037 %) + Sodium acetate trihydrate (0.37 %) + Sodium chloride (0.53 %)SolutionIntravenousECZACIBAŞI-BAXTER HASTANE ÜRÜNLERİ SAN.VE TİC. A.Ş.2020-08-14Not applicableTurkey flag

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of inorganic compounds known as alkali metal phosphates. These are inorganic compounds in which the largest oxoanion is phosphate, and in which the heaviest atom not in an oxoanion is an alkali metal.
Kingdom
Inorganic compounds
Super Class
Mixed metal/non-metal compounds
Class
Alkali metal oxoanionic compounds
Sub Class
Alkali metal phosphates
Direct Parent
Alkali metal phosphates
Alternative Parents
Inorganic sodium salts / Inorganic oxides
Substituents
Alkali metal phosphate / Inorganic oxide / Inorganic salt / Inorganic sodium salt
Molecular Framework
Not Available
External Descriptors
sodium phosphate (CHEBI:34683)
Affected organisms
Not Available

Chemical Identifiers

UNII
22ADO53M6F
CAS number
7558-79-4
InChI Key
BNIILDVGGAEEIG-UHFFFAOYSA-L
InChI
InChI=1S/2Na.H3O4P/c;;1-5(2,3)4/h;;(H3,1,2,3,4)/q2*+1;/p-2
IUPAC Name
disodium hydrogen phosphate
SMILES
[Na+].[Na+].OP([O-])([O-])=O

References

General References
  1. Rex DK: Dosing considerations in the use of sodium phosphate bowel preparations for colonoscopy. Ann Pharmacother. 2007 Sep;41(9):1466-75. Epub 2007 Jul 24. [Article]
  2. Schanz S, Kruis W, Mickisch O, Kuppers B, Berg P, Frick B, Heiland G, Huppe D, Schenck B, Horstkotte H, Winkler A: Bowel Preparation for Colonoscopy with Sodium Phosphate Solution versus Polyethylene Glycol-Based Lavage: A Multicenter Trial. Diagn Ther Endosc. 2008;2008:713521. doi: 10.1155/2008/713521. [Article]
  3. Ehrenpreis ED: Increased serum phosphate levels and calcium fluxes are seen in smaller individuals after a single dose of sodium phosphate colon cleansing solution: a pharmacokinetic analysis. Aliment Pharmacol Ther. 2009 Jun 1;29(11):1202-11. doi: 10.1111/j.1365-2036.2009.03987.x. Epub 2009 Feb 27. [Article]
  4. Razzaque MS: Phosphate toxicity: new insights into an old problem. Clin Sci (Lond). 2011 Feb;120(3):91-7. doi: 10.1042/CS20100377. [Article]
  5. Biber J, Hernando N, Forster I: Phosphate transporters and their function. Annu Rev Physiol. 2013;75:535-50. doi: 10.1146/annurev-physiol-030212-183748. [Article]
  6. FDA Guide: Sodium Phosphate Tablet [Link]
  7. ChemIDPlus: Sodium Phosphate [Link]
KEGG Compound
C13558
ChemSpider
22625
ChEBI
34683
ChEMBL
CHEMBL1060

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4CompletedTreatmentColon Cleansing1
4CompletedTreatmentObstructive Sleep Apnea (OSA) / Psoriasis (PsO)1
4Not Yet RecruitingTreatmentCritical Care1
3CompletedNot AvailableColonoscopy1
3CompletedTreatmentBowel preparation therapy1
3CompletedTreatmentCataracts2
2CompletedTreatmentAcute Lymphoblastic Leukemia (ALL)1
2Not Yet RecruitingTreatmentNasopharyngeal Neoplasms1
2RecruitingPreventionCataracts / Ocular Inflammation1
2RecruitingTreatmentAcute Kidney Injury (AKI) / Anticoagulation / Biphozyl / Continuous Renal Replacement Therapy / Continuous Venovenous Hemofiltration / Critically Ill Patients / Fluid replacement therapy / Phoxilium / Regional Citrate Anticoagulation (RCA) / Renal Replacement Therapies1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
SolutionIntravenous10.50 g/1000ml
Injection, solutionIntravenous
Powder, for solutionIntraocular
SolutionHemodialysis; Intravenous
SolutionHemodialysis; Intravenous0.187 g/L
SolutionIntravenous
Kit; solutionIntraocular
Solution, concentrateRectal
SolutionRectal
LiquidOral
EnemaRectal7 g/118ml
EnemaRectal3.5 g/59ml
KitIntravenous
SolutionUnknown
Tablet, coatedOral
LiquidBuccal
SprayBuccal
Kit; solutionIntraocular; Irrigation
LiquidTopical
Tablet, effervescentOral
EmulsionIntravenous
EmulsionParenteral
TabletOral
SolutionOral
Solution
SolutionOral1.2 g/5ml
SolutionHemodialysis
SolutionIntravenous0.225 g/L
InjectionIntravenous
EnemaRectal
SolutionRespiratory (inhalation)
Injection, solution, concentrateIntravenous
PowderOral
SolutionOral0.9 g/5ml
IrrigantIrrigation
SolutionIrrigation
LiquidIrrigation
Syrup
Prices
Not Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)Region
US7687075No2010-03-302028-06-22US flag

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
logP-1ChemAxon
pKa (Strongest Acidic)1.8ChemAxon
Physiological Charge-2ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area83.42 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity12.41 m3·mol-1ChemAxon
Polarizability5.24 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Transporters

Kind
Protein
Organism
Humans
Pharmacological action
No
General Function
Not Available
Specific Function
Not Available
Gene Name
SLC20A1
Uniprot ID
Q8WUM9
Uniprot Name
Sodium-dependent phosphate transporter 1
Molecular Weight
73699.01 Da
References
  1. Biber J, Hernando N, Forster I: Phosphate transporters and their function. Annu Rev Physiol. 2013;75:535-50. doi: 10.1146/annurev-physiol-030212-183748. [Article]
Kind
Protein
Organism
Humans
Pharmacological action
No
General Function
Virus receptor activity
Specific Function
Sodium-phosphate symporter which seems to play a fundamental housekeeping role in phosphate transport by absorbing phosphate from interstitial fluid for normal cellular functions such as cellular m...
Gene Name
SLC20A2
Uniprot ID
Q08357
Uniprot Name
Sodium-dependent phosphate transporter 2
Molecular Weight
70391.755 Da
References
  1. Biber J, Hernando N, Forster I: Phosphate transporters and their function. Annu Rev Physiol. 2013;75:535-50. doi: 10.1146/annurev-physiol-030212-183748. [Article]
Kind
Protein
Organism
Humans
Pharmacological action
No
General Function
Sodium:phosphate symporter activity
Specific Function
Involved in actively transporting phosphate into cells via Na(+) cotransport in the renal brush border membrane. Probably mediates 70-80% of the apical influx.
Gene Name
SLC34A1
Uniprot ID
Q06495
Uniprot Name
Sodium-dependent phosphate transport protein 2A
Molecular Weight
68936.53 Da
References
  1. Biber J, Hernando N, Forster I: Phosphate transporters and their function. Annu Rev Physiol. 2013;75:535-50. doi: 10.1146/annurev-physiol-030212-183748. [Article]
Kind
Protein
Organism
Humans
Pharmacological action
No
General Function
Sodium:phosphate symporter activity
Specific Function
May be involved in actively transporting phosphate into cells via Na(+) cotransport. It may be the main phosphate transport protein in the intestinal brush border membrane. May have a role in the s...
Gene Name
SLC34A2
Uniprot ID
O95436
Uniprot Name
Sodium-dependent phosphate transport protein 2B
Molecular Weight
75758.535 Da
References
  1. Biber J, Hernando N, Forster I: Phosphate transporters and their function. Annu Rev Physiol. 2013;75:535-50. doi: 10.1146/annurev-physiol-030212-183748. [Article]
Kind
Protein
Organism
Humans
Pharmacological action
No
General Function
Sodium:phosphate symporter activity
Specific Function
May be involved in actively transporting phosphate into cells via Na(+) cotransport in the renal brush border membrane. Probably mediates 20-30% of the apical influx.
Gene Name
SLC34A3
Uniprot ID
Q8N130
Uniprot Name
Sodium-dependent phosphate transport protein 2C
Molecular Weight
63548.94 Da
References
  1. Kirchheiner J, Meineke I, Muller G, Roots I, Brockmoller J: Contributions of CYP2D6, CYP2C9 and CYP2C19 to the biotransformation of E- and Z-doxepin in healthy volunteers. Pharmacogenetics. 2002 Oct;12(7):571-80. [Article]

Drug created at July 11, 2018 17:31 / Updated at January 08, 2021 01:07